Cargando…
Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment
Novel strategies for prostate cancer therapy are required to overcome resistance to abiraterone and enzalutamide. Here, we show that increasing 3βHSD1 after abiraterone and enzalutamide treatment is essential for drug resistance, and biochanin A (BCA), as an inhibitor of 3βHSD1, overcomes drug resis...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133401/ https://www.ncbi.nlm.nih.gov/pubmed/35584629 http://dx.doi.org/10.1016/j.xcrm.2022.100608 |
_version_ | 1784713558436610048 |
---|---|
author | Mei, Zejie Yang, Tao Liu, Ying Gao, Yuanyuan Hou, Zemin Zhuang, Qian He, Dongyin Zhang, Xuebin Tan, Qilong Zhu, Xuyou Qin, Yingyi Chen, Xi Xu, Chengdang Bian, Cuidong Wang, Xinan Wang, Chenyang Wu, Denglong Huang, Shengsong Li, Zhenfei |
author_facet | Mei, Zejie Yang, Tao Liu, Ying Gao, Yuanyuan Hou, Zemin Zhuang, Qian He, Dongyin Zhang, Xuebin Tan, Qilong Zhu, Xuyou Qin, Yingyi Chen, Xi Xu, Chengdang Bian, Cuidong Wang, Xinan Wang, Chenyang Wu, Denglong Huang, Shengsong Li, Zhenfei |
author_sort | Mei, Zejie |
collection | PubMed |
description | Novel strategies for prostate cancer therapy are required to overcome resistance to abiraterone and enzalutamide. Here, we show that increasing 3βHSD1 after abiraterone and enzalutamide treatment is essential for drug resistance, and biochanin A (BCA), as an inhibitor of 3βHSD1, overcomes drug resistance. 3βHSD1 activity increases in cell lines, biopsy samples, and patients after long-term treatment with enzalutamide or abiraterone. Enhanced steroidogenesis, mediated by 3βHSD1, is sufficient to impair enzalutamide function. In patients, accelerated abiraterone metabolism results in a decline of plasma abiraterone as disease progresses. BCA inhibits 3βHSD1 and suppresses prostate cancer development alone or together with abiraterone and enzalutamide. Daidzein, a BCA analog of dietary origin, is associated with higher plasma abiraterone concentrations and prevented prostate-specific antigen (PSA) increases in abiraterone-resistant patients. Overall, our results show that 3βHSD1 is a promising target to overcome drug resistance, and BCA suppresses disease progression as a 3βHSD1 inhibitor even after abiraterone and enzalutamide resistance. |
format | Online Article Text |
id | pubmed-9133401 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-91334012022-05-27 Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment Mei, Zejie Yang, Tao Liu, Ying Gao, Yuanyuan Hou, Zemin Zhuang, Qian He, Dongyin Zhang, Xuebin Tan, Qilong Zhu, Xuyou Qin, Yingyi Chen, Xi Xu, Chengdang Bian, Cuidong Wang, Xinan Wang, Chenyang Wu, Denglong Huang, Shengsong Li, Zhenfei Cell Rep Med Article Novel strategies for prostate cancer therapy are required to overcome resistance to abiraterone and enzalutamide. Here, we show that increasing 3βHSD1 after abiraterone and enzalutamide treatment is essential for drug resistance, and biochanin A (BCA), as an inhibitor of 3βHSD1, overcomes drug resistance. 3βHSD1 activity increases in cell lines, biopsy samples, and patients after long-term treatment with enzalutamide or abiraterone. Enhanced steroidogenesis, mediated by 3βHSD1, is sufficient to impair enzalutamide function. In patients, accelerated abiraterone metabolism results in a decline of plasma abiraterone as disease progresses. BCA inhibits 3βHSD1 and suppresses prostate cancer development alone or together with abiraterone and enzalutamide. Daidzein, a BCA analog of dietary origin, is associated with higher plasma abiraterone concentrations and prevented prostate-specific antigen (PSA) increases in abiraterone-resistant patients. Overall, our results show that 3βHSD1 is a promising target to overcome drug resistance, and BCA suppresses disease progression as a 3βHSD1 inhibitor even after abiraterone and enzalutamide resistance. Elsevier 2022-04-20 /pmc/articles/PMC9133401/ /pubmed/35584629 http://dx.doi.org/10.1016/j.xcrm.2022.100608 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Mei, Zejie Yang, Tao Liu, Ying Gao, Yuanyuan Hou, Zemin Zhuang, Qian He, Dongyin Zhang, Xuebin Tan, Qilong Zhu, Xuyou Qin, Yingyi Chen, Xi Xu, Chengdang Bian, Cuidong Wang, Xinan Wang, Chenyang Wu, Denglong Huang, Shengsong Li, Zhenfei Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment |
title | Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment |
title_full | Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment |
title_fullStr | Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment |
title_full_unstemmed | Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment |
title_short | Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment |
title_sort | management of prostate cancer by targeting 3βhsd1 after enzalutamide and abiraterone treatment |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133401/ https://www.ncbi.nlm.nih.gov/pubmed/35584629 http://dx.doi.org/10.1016/j.xcrm.2022.100608 |
work_keys_str_mv | AT meizejie managementofprostatecancerbytargeting3bhsd1afterenzalutamideandabirateronetreatment AT yangtao managementofprostatecancerbytargeting3bhsd1afterenzalutamideandabirateronetreatment AT liuying managementofprostatecancerbytargeting3bhsd1afterenzalutamideandabirateronetreatment AT gaoyuanyuan managementofprostatecancerbytargeting3bhsd1afterenzalutamideandabirateronetreatment AT houzemin managementofprostatecancerbytargeting3bhsd1afterenzalutamideandabirateronetreatment AT zhuangqian managementofprostatecancerbytargeting3bhsd1afterenzalutamideandabirateronetreatment AT hedongyin managementofprostatecancerbytargeting3bhsd1afterenzalutamideandabirateronetreatment AT zhangxuebin managementofprostatecancerbytargeting3bhsd1afterenzalutamideandabirateronetreatment AT tanqilong managementofprostatecancerbytargeting3bhsd1afterenzalutamideandabirateronetreatment AT zhuxuyou managementofprostatecancerbytargeting3bhsd1afterenzalutamideandabirateronetreatment AT qinyingyi managementofprostatecancerbytargeting3bhsd1afterenzalutamideandabirateronetreatment AT chenxi managementofprostatecancerbytargeting3bhsd1afterenzalutamideandabirateronetreatment AT xuchengdang managementofprostatecancerbytargeting3bhsd1afterenzalutamideandabirateronetreatment AT biancuidong managementofprostatecancerbytargeting3bhsd1afterenzalutamideandabirateronetreatment AT wangxinan managementofprostatecancerbytargeting3bhsd1afterenzalutamideandabirateronetreatment AT wangchenyang managementofprostatecancerbytargeting3bhsd1afterenzalutamideandabirateronetreatment AT wudenglong managementofprostatecancerbytargeting3bhsd1afterenzalutamideandabirateronetreatment AT huangshengsong managementofprostatecancerbytargeting3bhsd1afterenzalutamideandabirateronetreatment AT lizhenfei managementofprostatecancerbytargeting3bhsd1afterenzalutamideandabirateronetreatment |